Histogenics (NASDAQ:HSGX) has been assigned a $4.00 target price by analysts at HC Wainwright in a research report issued on Wednesday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. HC Wainwright’s price target points to a potential upside of 94.17% from the stock’s current price.
Other analysts have also recently issued reports about the company. Zacks Investment Research raised Histogenics from a “hold” rating to a “buy” rating and set a $2.00 price objective for the company in a research report on Thursday, September 7th. Canaccord Genuity reaffirmed a “buy” rating and set a $4.00 price objective on shares of Histogenics in a research report on Thursday, December 21st.
Shares of Histogenics (NASDAQ:HSGX) opened at $2.06 on Wednesday. The stock has a market capitalization of $49.10, a PE ratio of -1.49 and a beta of 1.43. Histogenics has a 1 year low of $1.45 and a 1 year high of $2.40.
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.